US Patent

US8759329 — Testosterone gel and method of use

Formulation · Assigned to Besins Healthcare Luxembourg SARL · Expires 2026-10-12 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an improved transdermal hydroalcoholic testosterone gel formulation and methods of its use.

USPTO Abstract

The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.

Drugs covered by this patent

Patent Metadata

Patent number
US8759329
Jurisdiction
US
Classification
Formulation
Expires
2026-10-12
Drug substance claim
No
Drug product claim
Yes
Assignee
Besins Healthcare Luxembourg SARL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.